Experimental lymphoma drug shows early promise in tiny study
NCT ID NCT04676360
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times
Summary
This study tested a drug called belantamab mafodotin (Blenrep) in 10 people with rare, aggressive lymphomas that had come back or not responded to treatment. The drug is an antibody-drug conjugate designed to target and kill lymphoma cells. The trial was terminated early, so the full results are not available, but researchers were looking at how many patients responded and what side effects occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED PLASMABLASTIC LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (Blenrep)
What this could lead to
If successful, this could point toward a new treatment option for rare, aggressive lymphomas that have not responded to other therapies.
What could go wrong
This trial was terminated early and enrolled only 10 people, so results are very limited. The drug may cause side effects like eye problems, and it is unclear if it works better than existing options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.